About Novacyt
Novacyt is a company based in Velizy-villacoublay (France) founded in 2005. Novacyt has completed 4 acquisitions, including IT-IS, Lab21 and Primerdesign. Novacyt operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter Velizy-villacoublay, France
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novacyt Sas
-
Annual Revenue
$24.09 M (USD)89.89as on Dec 31, 2024
-
Net Profit
-$51.25 M (USD)-51.64as on Dec 31, 2024
-
EBITDA
-$11.05 M (USD)22.09as on Dec 31, 2024
-
Latest Funding Round
$4.72 M (USD), Debt – Conventional
May 30, 2018
-
Investors
Kreos Capital
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
IT-IS
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Novacyt
Novacyt is a publicly listed company on the EURONEXT with ticker symbol ALNOV in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Novacyt
Unlock access to complete
Unlock access to complete
Funding Insights of Novacyt
Investors in Novacyt
Novacyt has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Kreos Capital and Eiffel Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt is provided to growth-stage companies across multiple sectors.
|
Locked | Locked | Locked | |
|
Private equity and private debt firm focused on multiple sector
|
Locked | Locked | Locked |
Investor details for Novacyt
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novacyt
Novacyt has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include IT-IS, Lab21 and Primerdesign.
Investment portfolio details for Novacyt
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Clinical research, trials, and biomarker discovery services are offered.
|
Locked | Locked | 2013 | Locked | |
|
Personalised diagnostic testing for diseases and predisposition is specialised in.
|
Locked | Locked | 2005 | Locked | |
|
Real-time PCR kits and reagents using its technology
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Novacyt
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Novacyt
Detailed financials for Novacyt
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novacyt Comparisons
Peer comparison for Novacyt
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novacyt
Novacyt operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
|
Detailed competitors of Novacyt
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novacyt
Complete news archive for Novacyt
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novacyt
Novacyt was founded in 2005 and raised its 1st funding round 9 years after it was founded.
Novacyt is headquartered in Velizy-villacoublay, France. It is registered at Velizy-villacoublay, Ile-de-france, France.
Annual revenue of Novacyt is $24.09M as on Dec 31, 2024.
Novacyt was founded in 2005 in Velizy Villacoublay, France, as a developer of cytology instruments and consumables focused on oncology and infectious disease sectors. Cellular diagnostics are emphasized through a portfolio of products and services for cancer and infectious disease applications. Operations center on proprietary platform technology NovaPrep, an automated liquid cytology instrument used for cancer diagnosis. The company operates primarily in the medical diagnostics industry.
Novacyt's top competitors include Guardant Health, Foundation Medicine and Natera.
Yes, Novacyt is publicly traded on EURONEXT under the ticker symbol ALNOV.
Novacyt has made 4 acquisitions, including IT-IS, Lab21, and Primerdesign.
Novacyt has 2 investors. Key investors include Kreos Capital, and Eiffel Investment Group.
The ticker symbol of Novacyt is ALNOV on EURONEXT.